Lercanidipine Almus (Lercanidipine Hydrochloride)

Lercanidipine blocks L-type calcium channels in the smooth muscle of arterial walls. This inhibition prevents calcium‑mediated contraction, causing vasodilation, decreasing peripheral resistance, and ultimately lowering systemic blood pressure.

The appropriate dose of Lercanidipine Almus is determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any concomitant medications. No fixed regimen is provided here.

Safety of Lercanidipine in pregnancy and lactation has not been established. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and only under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Both Lercanidipine and amlodipine belong to the dihydropyridine calcium‑channel blocker class and lower blood pressure by vasodilation. Lercanidipine has a longer half‑life, allowing once‑daily dosing, and may exhibit a slightly lower incidence of peripheral edema compared with amlodipine in some studies.

Store Lercanidipine tablets at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Lercanidipine is taken orally, usually as a whole tablet swallowed with a glass of water. It is typically administered once daily, with or without food, as directed by the prescribing clinician.

Serious adverse events include severe hypotension, angioedema, myocardial infarction, and hepatic dysfunction. Patients should be monitored for sudden drops in blood pressure, swelling of the face or throat, chest pain, and signs of liver injury, and seek immediate medical attention if they occur.

Lercanidipine is contraindicated in individuals with known hypersensitivity to the drug, severe aortic stenosis, cardiogenic shock, or uncontrolled heart failure. It should also be avoided in pregnant or breastfeeding women unless clearly indicated by a healthcare professional.